Corporate Member Update: New Treatment Option for Some Patients With Triple-Class Refractory Multiple Myeloma

Oncopeptides would like to invite the Nebraska Oncology Society members to:

Discover a New Treatment Option for Some Patients With Triple-Class Refractory Multiple Myeloma

Join Oncopeptides on

• Tuesday, April 13 at 6pm ET or 8:30pm ET
• Wednesday, April 14 at 12pm ET or 3pm ET

for a live broadcast featuring Dr. Mikhael and Dr. Richter, who will discuss a newly approved therapy for adult patients with multiple myeloma who have received at least four prior lines of
therapy and are triple-class refractory.

Click on this link for more information, or register here.